EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients With Postsurgical Recurrence . J. Can. Res. Updates 2012, 1 (1),  102-107. https://doi.org/10.6000/1929-2279.2012.01.01.15.